ICON PLC - ICLR STOCK NEWS

ICON plc (NASDAQ: ICLR) has announced participation in two upcoming conferences. CFO Brendan Brennan will present at the 30th Annual Credit Suisse Healthcare Conference on November 9, 2021, at 8:50 AM ET, and at the 4th Annual Evercore ISI HealthCONx Conference on December 1, 2021, at 12:10 PM ET. Investors can find updates and links to live webcasts on the company's Investor Relations website. With approximately 37,960 employees across 159 locations worldwide, ICON focuses on advancing clinical research and improving patient lives.

ICON plc (NASDAQ: ICLR) reported impressive Q3 2021 results with record net business wins of $2,374 million and a net book to bill ratio of 1.27. Adjusted revenue reached $1,870.4 million, marking a 167% year-on-year increase. Adjusted net income was $209.8 million, or $2.55 per diluted share. However, GAAP net loss reached $94.3 million. The company revised its full-year revenue guidance to $5,430 - $5,530 million, a 94% - 98% increase year-on-year.

ICON plc has received a €4 million funding grant from Enterprise Ireland, aimed at enhancing its digital health technology and data analytics solutions. This R&D support will facilitate the development of decentralized clinical trial technology, providing participants with options for virtual visits and mobile reporting. This strategic investment aims to improve clinical trial efficiency and participation, reduce costs, and ensure real-time data access. The funding highlights ICON's commitment to advancing clinical research and delivering better patient outcomes globally.

ICON plc (NASDAQ: ICLR) announced that CFO Brendan Brennan will present at two upcoming healthcare conferences. He will speak at the Wells Fargo 16th Annual Healthcare Conference on September 9, 2021, at 8:00 AM ET, and at the Baird Global Healthcare Conference on September 15, 2021, at 8:30 AM ET.

Investors can find updates on these events and links to live webcasts on the Investor section of ICON's website. As of June 30, 2021, ICON employed approximately 16,480 employees across 89 locations worldwide.

ICON plc (NASDAQ: ICLR) reported a strong Q2 2021, showcasing a record net business win of $1,106 million and a remarkable revenue increase of 40.5% year-over-year to $871 million. Adjusted EPS surged by 76.8% to $2.12. The acquisition of PRA is poised to enhance growth and shareholder value, with updated revenue guidance for 2021 between $5,300 million and $5,500 million. Cash generated from operations was $128.4 million, while net cash reached $707.2 million. Overall, the results highlight a robust financial position and positive outlook for the company.

ICON plc (NASDAQ: ICLR) successfully held its Annual General Meeting (AGM) on July 20, 2021, where all recommended resolutions were passed by shareholders. Key resolutions included re-election of directors, approval of financial reports, and authorizations for share allotment and market purchases. Approximately 45.4 million votes were cast. Notable outcomes were re-elections of Ciaran Murray, Joan Garahy, and Eugene McCague, alongside approvals for the fixing of auditors’ remuneration and disapplication of pre-emption rights. The company continues to emphasize growth and innovation in clinical research.

ICON plc (NASDAQ: ICLR) has completed its acquisition of PRA Health Sciences, forming a combined entity with 38,000 employees across 47 countries. The merger aims to create a leading healthcare intelligence and clinical research organization, enhancing clinical trials and accelerating drug development through advanced technology and diverse patient access. PRA shareholders received $80 in cash and 0.4125 shares of ICON stock. This strategic move positions ICON to improve biopharma customers' success in bringing essential medicines and devices to market.

ICON plc (NASDAQ: ICLR) announced the proposed acquisition of PRA Health Sciences, with the merger set to occur through ICON's wholly-owned subsidiary. The company plans to issue $500 million in Senior Secured Notes at 2.875% interest due 2026, replacing a previously planned offering of $1,515 million in 2028 notes due to an increase in credit facilities. The proceeds will fund the merger payment, refinance existing debt, and cover related expenses. The offering is expected to close on July 1, 2021, pending customary conditions.

ICON (NASDAQ: ICLR) announced the successful passing of all resolutions at its Extraordinary General Meeting held on June 15, 2021. Shareholders approved the issuance of ordinary shares related to the acquisition of PRA Health Sciences. The merger will see PRA operate as a subsidiary of ICON. Furthermore, PRA's stockholders also voted to adopt the Merger Agreement and approve executive compensation arrangements tied to the transaction. The merger is expected to close on July 1, 2021, pending any remaining conditions.